Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi

Haematologica. 2016 May;101(5):e196-9. doi: 10.3324/haematol.2015.139329. Epub 2016 Feb 8.

¹ Department of Diagnostic, Clinical and Public Health Medicine University of Modena and Reggio Emilia, Rimini stefano.sacchi@unimore.it.
² Department of Diagnostic, Clinical and Public Health Medicine University of Modena and Reggio Emilia, Rimini.
³ Division of Hematology, University of Pisa, Rimini.
⁴ Hematology Unit, Infermi Hospital, Rimini.
⁵ Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Piacenza.
⁶ Hematology Unit, Guglielmo da Saliceto Hospital, Piacenza.
⁷ Hematology and SCT Unit, IRCCS-CROB, Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Meldola.
⁸ Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola.
⁹ Unit of Hematology with Transplantation, Department of Emergency and Organ Transplantation, University of Bari, Reggio Emilia.
¹⁰ Department of Biomedical Sciences and Human Oncology, University of Bari "A. Moro", Reggio Emilia.
¹¹ Division of Internal Medicine, Cesena Hospital, Hematology Unit, Azienda Ospedaliera Arcispedale Santa Maria Nuova, IRCCS, Reggio Emilia.
¹² Department of Hematology, Città della Salute e della Scienza Hospital and University of Torino, Genova.
¹³ Hematology Unit, San Martino Hospital, Genova.
¹⁴ Department of Hematology & Oncology, Humanitas Cancer Center, Humanitas Clinical & Research, Rozzano.
¹⁵ Division of Haematology, AOU "Policlinico-Vittorio Emanuele", University of Catania, Italy.

No abstract available

Keywords: efficacy; indolent; lenalidomide; non-follicular lymphoma; recurrent; rituximab; safety.

Publication types